Advances in PSMA theranostics

Thomas M. Jeitner a, John W. Babich a,b,c,1, James M. Kelly a,b,c, *

a Molecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medicine, Belfer Research Building, 413 East 69th Street, Room BB-1604, New York, NY 10021, USA
b Weill Cornell Medicine, Sandra and Edward Meyer Cancer Center, New York, NY 10021, USA
c Weill Cornell Medicine, Citigroup Biomedical Imaging Center, New York, NY 10021, USA

ARTICLE INFO

Keywords:
PSMA
Theranostics
Targeted radioligand therapy
Targeted alpha therapy

ABSTRACT

The validation of prostate specific membrane antigen (PSMA) as a molecular target in metastatic castration-resistant prostate cancer has stimulated the development of multiple classes of theranostic ligands that specifically target PSMA. Theranostic ligands are used to image disease or selectively deliver cytotoxic radioactivity to cells expressing PSMA according to the radioisotope conjugated to the ligand. PSMA theranostics is a rapidly advancing field that is now integrating into clinical management of prostate cancer patients. In this review we summarize published research describing the biological role(s) and activity of PSMA, highlight the most clinically advanced PSMA targeting molecules and biomacromolecules, and identify next generation PSMA ligands that aim to further improve treatment efficacy. The goal of this review is to provide a comprehensive assessment of the current state-of-play and a roadmap to achieving further advances in PSMA theranostics.

Introduction

Prostate specific membrane antigen (PSMA) is highly and selectively expressed on prostate cancer cells. Consequently, there is significant interest in ligands that bind PSMA as a means of visualizing and treating these cancers. Despite the interest in PSMA, its functions in normal or neoplastic prostate cells are poorly understood. Understanding the biology of this protein may inform efforts to better target PSMA and the associated cancers, just as the use of PSMA ligands has already indicated new aspects of prostate cancers and its treatment. Here, we provide a brief review of the biology of PSMA, as well as an overview of ongoing efforts to develop PSMA ligands as theranostic (diagnostic + therapeutic) agents.

Part 1: the biology and biochemistry of PSMA

PSMA: gene and proteins

PSMA is known by several names - glutamate carboxypeptidase II (GCPII), N-acetylated-α-linked acidic dipeptidase [1,2], and folate hydrolase (FOLH1) [3,4] - which reflect the activities of this enzyme in different tissues. These proteins are actively transcribed from one of two copies of the FOLH1 gene. The relevant gene is situated at position 11.12 on the p arm of chromosome 11 (GenBank: AF007544) [5,6], while a pseudogene is located on the other arm at position 11.14 [7]. A total of 19 exons and 18 introns [5,6] comprise the gene, which also contains multiple start sites that give rise to distinct products at different sites [2,8–13]. Of these products, PSMA and FOLH1 are 100% homologous [10] while PSMA/FOLH1 and GCPII are 83% homologous [14–16]. Normal prostate cells express an FOLH1 transcript that encodes a cytoplasmic protein of unknown function [9,11,17,18]. By contrast, cancerous prostate cells produce full-length PSMA [19]. The expression of this protein increases as a function of cancer progression [20], Gleason score, and serum PSA levels [21]. PSMA expression, however, is not restricted to prostate cancer. Endothelial cells from virtually all other cancers also express PSMA [19,22–31]. In addition, normal tissues, such as the small intestine, kidney nephron, brain, and salivary glands, express PSMA [4,16,32–36].

Although a promoter for FOLH1 exists [6], the prostate-specific expression of PSMA is primarily controlled by a cis acting element known as the PSMA enhancer or PSME [37]. Binding of NFATc1 to AP-3

Note: We do not feel that a graphical abstract is required for this review article, but submit the following for consideration.

1 Corresponding author at: Department of Radiology, Weill Cornell Medicine, Molecular Imaging Innovations Institute, Belfer Research Building, 413 East 69th Street, Room BB-1604, New York, NY 10021, USA.
E-mail address: jak2046@med.cornell.edu (J.M. Kelly).
1 Present address: Ratio Therapeutics, Inc, Boston, MA, USA.
site in the 5′ end of PSME facilitates PSMA expression [38], whereas binding Sox7 to a number of sites within PSME suppress its expression [39,40]. Sox7 is frequently inactivated in prostate cancer by promoter hyper-methylation, in agreement with the enhanced expression of PSMA in some forms of this cancer [41]. PSME driven expression is also repressed by androgens consistent with its role in prostate biology and carcinogenesis [37].

FOLH1 encodes a 750-residue membrane-associated, dinuclear zinc peptidase with an apparent molecular mass of 110 kDa [42]. Glycosylation accounts for the disparity between the predicted and apparent mass. The bulk of this enzyme is resides on the outer surface of the plasma membrane tethered by a membrane-spanning segment of 22 amino acids. An additional 19 residues project into the cytoplasm. The extracellular portion folds into three domains, the protease, apical and C-terminal domains [43]. FOLH1 dimerizes to form the active enzyme with the C-terminus of one monomer interfacing with the protease and apical regions of the other monomer. The enzymes encoded by FOLH1 catalyze the hydrolysis of terminal glutaminyl residues from substrates bearing glutaminyl (N-acetyl aspartylglutamate: NAAG) or polyglutaminyl residues (folates). Substrates bind to the enzyme by way of a hairpin formed from a β sheet in the C-terminal domain. The hairpin situates specific lysyl (K699) and tyrosyl (Y700) residues in close proximity the carboxyl moieties of the glutamate portion of the substrate and effectively sense the glutamate portion of the substrate (Fig. 1). This sensing involves the ε-amino group of the lysyl residue forming a salt bridge with the γ-carboxyl group and the hydroxyl group of the tyrosyl residue to form a hydrogen bond with the α-carboxyl group of the glutaratic moiety. Binding of the substrate induces conformational changes that position the amide of the glutamyl substrate so that it hydrogen-bonds with the γ-carboxyl group of a glutamyl residue (E424) in the active site, causing the now basic active-site glutamate to abstract a proton from a water molecule ligated by two zinc atoms. The resulting hydroxyl ion then attacks the proffered peptide bond of the bound substrate. Following hydrolysis, the catalytic glutamyl residue shuttles the proton to the amino group of the leaving product.

GCPII and the regulation of extrasynaptic glutamate and NAAG pools

Arguably, some of the most exciting and informative recent work on PSMA comes from studies of GCPII in the brain, where it contributes to several major pathologies. GCPII (EC 3.4.17.21) acts to catabolize extrasynaptic NAAG in the brain [16,32,44]. NAAG is the most abundant peptide neurotransmitter present in the brain, as well as the third most prevalent neurotransmitter overall [45,46]. These rankings equate to millimolar amounts of NAAG in the brain. Consequently, hydrolysis of NAAG by GCPII yields millimolar quantities of glutamate. Additional amounts of glutamate are also released from the same neurons that release NAAG [45] and through the actions of another NAAG peptidase termed glutamate carboxypeptidase III (EC 3.4.17.11) [47,48]. Glutamate is the most potent excitatory neurotransmitter in the brain and excess levels elicit lethal accumulations of intraneuronal calcium following its engagement with post-synaptic N-methyl-D-aspartate (NMDA) receptors [49]. NAAG is also an NMDA antagonist [50]. Thus, its catabolism will augment signaling via NMDA receptors. Astrocytes and other glial cells protect the brain from excitotoxicity by scavenging glutamate. The scavenged glutamate is then converted to either 2-oxoglutarate (α-ketoglutarate) for anaplerosis, or to glutamine for export to the neighboring neuron [51]. However, pathological conditions result in the accumulation of NAAG to such high levels that the resulting amounts of glutamate exceed the capacity of neighboring glia to effectively scavenger it. The ensuring excitotoxicity contributes to neurodegeneration. GCPII inhibitors, therefore, hold great promise in the treatment of neurodegenerative diseases like Alzheimer Disease and amyotrophic lateral sclerosis [46,52]. Many of these inhibitors also form

![Fig. 1. Glutamate Sensing in the Glutamate Carboxypeptidase Active Site](image-url)
the basis of theranostics that target PSMA \[53\].

NAAG perpetuates its actions as a neurotransmitter by binding metabotropic glutamate receptor 3 (mGluR3), which is situated postsynaptically in the higher cortical circuits of primates \[54, 55\]. Activation of these receptors strengthens synaptic connectivity. Conversely, decreasing amounts of NAAG correlate with decreases in cognition \[54, 55\]. These decreases in NAAG, in turn, correlate with increased amounts of GCPII due enhanced transcription of a FOLH1 missense polymorphism (rs202676) \[56\] or cerebral inflammation \[57\]. The FOLH1 missense mutation (rs202676 G allele) is associated with increased levels of FOLH1 mRNA in the dorsolateral prefrontal cortex of the human brain. This increase in message is likely to be translated into GCPII given the decreased amount of NAAG measured in the centrum semiovale \[56\]. GCPII is expressed in astrocytes, microglia, neuoript, and neurons \[33, 57–61\]. Of these cells, astrocytes and microglia mediate the inflammatory response in the brain, and during inflammation these cells express elevated levels of GCPII \[57, 60–62\]. Datta et al. postulate that inflammation may also cause neurons to endocytose GCPII uptake based on neuronal GCPII staining in aging neurons \[57\] and neurons exposed to hypoxia or ischemia \[60\]. These cell specific increases in GCPII are evident in advanced aging \[57\] and multiple sclerosis \[52, 55\], both of which are associated with cognitive dysfunction \[63, 64\]. Importantly, GCPII inhibition improves cognition in animal models of aging \[57\] and multiple sclerosis \[52, 55\], as well as cerebral inflammation \[65\] and cognitively intact animals \[54\]. The use of GCPII inhibitors in the brain and periphery was recently reviewed elsewhere \[53\].

Despite the clear relationship between inflammation and GCPII expression, the role of inflammatory mediators – reactive oxygen species, reactive nitrogen species, or cytokines – in regulating this expression is poorly understood. Although lipopolysaccharide is not a cytokine, it causes cells to produce and release cytokines, and its addition to primary microglia markedly increases GCPII activity in these cells \[60\]. Similarly, CXCL1 significantly increased in the cortex of superoxide dismutase transgenic mice subjected neonatal hypoxic-ischemic brain injury \[61\]. Prior administration of a GCPII inhibitor to these mice mitigated the increase in CXCL1. Given the interplay of pro- and anti-inflammatory cytokines, more detailed studies of the role of these and other inflammatory mediators in GCPII expression is likely to yield more candidates for the regulation of this activity in physiological and pathological states.

**Intestinal PSMA or folate hydrolase 1 and folate metabolism**

The intestinal form of PSMA is situated on the jejunal brush border membrane where it converts dietary folates into a form capable of absorption by the small intestine \[4\] (Fig. 2). Folates encompass a series of compounds that contain a pteric acid moiety bound to a single glutamate (folic acid, 5-methyltetrahydrofolate, and folic acid) or a chain of \(\gamma\)-linked glutamates (polyglutamyl folic acids) \[66\]. Mammals cannot synthesize folate and must consume foods rich in these compounds – typically legumes – to obtain tetrahydrofolate, a crucial vitamin coenzyme for one-carbon metabolism. Put simply, one carbon metabolism refers to reactions involving methyl, methylene, and formyl group transfers. These groups are highly reactive and are therefore bound to carriers, such as tetrahydrofolate to facilitate their participation in metabolic processes. A common example of these reactions is the formation of 10-formyltetrahydrofolate or formyl folate, which is required for the biosynthesis of inosine monophosphate. The latter molecule is the precursor to GMP and AMP, which following modification to the

![Fig. 2. Folic Acid Metabolism](image-url)

---

**Reactions 1 and 2** are catalyzed by dihydrofolate reductase (EC 1.5.1.3): folic acid is reduced to dihydrofolate, which in turn is reduced to tetrahydrofolate. Serine hydroxymethyltransferase (EC 2.1.2.1) catalyzes reaction 3. The reaction product, \(N\text{-}N\text{\textsuperscript{5}}\text{-methylene tetrahydrofolate}\), can then be reduced to \(N\text{-}N\text{\textsuperscript{5}}\text{methyl tetrahydrofolate}\) by methylenetetrahydrofolate reductase (EC 1.5.1.20), as shown in reaction 4. Methyltetrahydrofolate, in turn, is the methyl donor for the methylation of homocysteine to form methionine, as catalyzed by homocysteine methyltransferase (EC 2.1.1.10, reaction 5). This reaction also regenerates tetrahydrofolate. Dihydrofolate is also regenerated through the actions of thymidylate synthase (EC 2.1.1.45, reaction 6), which catalyzes the reductive methylation of deoxyuridine monophosphate (dUMP) to form deoxythymidine monophosphate (dTMP). In this reaction, methyltetrahydrofolate is oxidized to dihydrofolate. dTMP is the source of the thymidine used to synthesized DNA. Note, the majority of the indicated changes affect the pteroyl portion of the folates and these are indicated in blue.
sugar backbone, gives rise to the nucleotides for nucleic acid synthesis. Dietary folate exists primarily with chains of greater than two glutamyl residues, e.g., pteroylhexaglutamate [66]. Intestinal absorption requires that γ-linked glutamates be removed from the polyglutamyl folates. In the case of polyglutamyl folic acid, this means conversion to folinic acid, and folate hydrolase 1 catalyzes the hydrolysis of γ-linked glutamyl moieties from polyglutamyl folates [4]. The contention that the enzyme favors the polyglutamyl folates is supported by the observation that polyglutamyl folic acid binds to the catalytic site more efficiently than does folic acid or its metabolite, 5-methyltetrahydrofolate (Fig. 2). The absorbed pteroyldiglutamate then collects in the hepatic vein for transport to the liver for reduction to methyltetrahydrofolate: the major circulating form of folate [67, 68].

**Renal PSMA**

A diverse range of ligands cause PSMA to endocytose. These ligands range in size from antibodies to molecules with the dimensions of small peptides [69–72]. Neither the rates of PSMA internalization nor of recycling to plasmalemma are known. Even so, the endocytosis and recycling of PSMA are thought to be similar that of the transferrin receptor given the characteristic of their leucine zipper domains as well as other structural and sequence similarities [6, 73]. Endocytosed PSMA and the transferrin receptor also appear in the same vacuoles [74]. The rates of transferrin receptor recycling should therefore approximate those of PSMA. The transferrin receptor recycles at a rate of 0.63 min⁻¹ [75], which implies that PSMA should recycle to plasmalemma within 2 min of internalization. The rate of this recycling decreases as a function of receptor number and as the size of the ligands increase [75, 76]. If this proves true for PSMA as well, small molecules should induce PSMA to endocytose more rapidly than do antibodies.

Renal and prostatic PSMA are thought to act as ancillary folate transporters, such that in the absence of cleavable substrate, pteroyldiglutamates cause PSMA to endocytose and deliver its cargo to cells [77]. This argument is based on the following observations: in the kidney, circulating folates are re-absorbed via renal tubular absorption from the blood by folate receptor alpha (FRα), and loss of this receptor significantly attenuates, but does not completely prevent folate re-uptake by the kidneys [78]. The continued uptake of folate in FRα-deficient animals implies the existence of another route for renal folate transport. One candidate for this transport is PSMA, which is also expressed in regions responsible for renal folate uptake [79]. Folic acid inhibits the folate hydrolase activity of PSMA, which implies that it binds PSMA at least transiently [77, 80]. PSMA also enables folic acid

Fig. 3. The structures of small molecule PSMA theranostic ligands discussed in this manuscript. The library is not exhaustive, but reflects the different classes of molecule currently under investigation. The compounds highlighted in the black square (PSMA-617 and PSMA-I&I) have undergone the most extensive clinical evaluation to date and are templates for next generation ligands. The compounds highlighted in the purple square are radiohalogenated PSMA inhibitors. Compounds in the blue box are albumin binding ligands based on PSMA-617, while the compounds in the red and orange boxes are albumin-binding ligands based on other platforms. Finally, the molecules in the gray box are PSMA ligands designed for 64/67Cu theranostics.
Prostate PSMA as a putative glutamate carboxypeptidase

Uptake by cells that express it [77]. Endocytosis and subsequent dissociation of the PSMA and folic acid is therefore the most likely mechanism for the ingress of folic acid. This hypothesis is supported heuristically by the observations that PSMA polymorphisms that decrease its enzymatic activity increase serum folate concentration in kidney transplant patients [81], as well as the renal uptake of highly selective ligands for PSMA [82-88].

The identities of the natural ligands for renal PSMA are not known. Since the circulating folates are all monoglutamyalted and therefore not subject to hydrolysis by glutamate carboxypeptidases, the binding of folate analogs to renal PSMA may serve as a mechanism for either recovery into the folate pool – as in the case of folic acid – or the elimination of the analogs. In other words, prolonged or high affinity occupancy of the PSMA folate binding site by folate analogs may promote endocytosis and the subsequent metabolism of the analogs. Folic acid can be reduced to methyltetrahydrofolate by dihydrofolate reductase and utilized in one-carbon metabolism (Fig. 2).

Salivary gland PSMA

Hominin salivary glands express low levels of PSMA [36,89-91]; moreover, this expression is restricted to specific sites, such as the intercalated ducts of submandibular glands [36]. This specificity presumably accounts of the equivocal reports of PSMA staining in these glands [19,36,89-91]. Despite the low expression of PSMA, salivary glands sequester PSMA ligands [36,82,92-95]. Given the discordance between PSMA expression and PSMA ligand sequestration by the salivary glands, Rupp et al. [36] hypothesize that an entity other than PSMA is responsible for the uptake of its ligands but do not suggest an alternate uptake mechanism for the PSMA ligands. This conclusion is supported by recent data confirming that only some of the binding to salivary glands is displaced by non-radioactive PSMA ligands, with a substantial fraction of the uptake appearing to be non-specific [96]. This is an important issue, because the salivary uptake of these ligands is the major impediment to the use of these agents as a means of delivering therapeutic doses of radiation to prostate cancer [93-95,97-99].

Prostate PSMA as a putative glutamate carboxypeptidase

Prostatic PSMA catalyzes the hydrolysis of γ-linked glutamate from polyglutamyl folates [80]. The relevant substrates for this reaction, however, are not present in the circulation. O’Keeffe et al. [100] proposed that these substrates may be derived from cells dying within the tumor mass. Tetrahydrofolate can be converted to polyglutamyl folate by way of polyglutamyl-γ-glutamate synthetase, and cells do contain polyglutamyl folate stores [101-103]. The liver contains the highest amount of polyglutamyl folate equal to 14 nmole per gram of rat tissue, equivalent to 12 μM polyglutamyl folate [103]. Just as in normal tissues, tumor masses exhibit ongoing cell death, albeit at a slower rate than that of cell proliferation. Again, just as in normal tissues, phagocytes consume dying cells in tumors. Cell lysis leading to the spillage of polyglutamyl folates is therefore an unlikely event in cancers. Notably, O’Keeffe et al. [100] did not provide any measurements of polyglutamyl folate release from tumors to support their hypothesis.

Prostatic PSMA is also proposed to act as a carboxypeptidase to cleave circulating pteroyldiglutamate to release glutamate to activate metabotropic glutamate receptors [104]. This proposal is based, in part, on the well-known hydrolysis of NAAG by GCPII to yield glutamate. In both cases, α-linked glutamate is released from either pteroyldiglutamate or NAAG. However, no direct measurements of this release from pteroyldiglutamate as catalyzed by PSMA exist. Instead, Kaittanis et al. [104] reported an indirect measurement of glutamate, namely an increase in glutamate-induced fluorescence following incubation of PSMA-bearing cells with pteroyldiglutamate. At the time of the incubation, the cells were starved of both pteroyldiglutamate and glutamate. Thus, pteroyldiglutamate was added to metabolically stressed cells under non-physiological conditions that could have promoted glutamine catabolism to supply glutamate. In other words, the glutamate-induced fluorescence could have been due to metabolic changes rather than to the activity of PSMA per se. In any case, the other major difficulty with this proposal is that serum levels of glutamate far exceed those of pteroyldiglutamate. Serum contains 51 μM glutamate [103] and between 20 and 60 nM pteroyldiglutamates, depending on age [67,68]. Thus, even if PSMA were to cleave glutamate from pteroyldiglutamate, the amounts released would be a thousand-fold lower than the amounts of glutamate already present in blood. Kaittanis et al. [104] also base their arguments on the apparent activation of signaling pathways by glutamate interacting with metabotropic glutamate receptors without considering that the same pathways are activated by endocytosis [105-108] that could also account for importation of folates.

While the above discussion argues against PSMA acting as a glutamate carboxypeptidase in prostate cancer, the truncated form of PSMA found in normal prostate tissues may be a γ-glutamyl hydrolase [109]. The latter protein shares the active site but not the cytoplasmic tail or transmembrane portions of the full length PSMA [11,18]. Thus, the truncated PSMA that is constrained to the cytoplasm may act to remove the glutamyl chains from the intracellular polyglutamyl folates when necessary.

Prostate PSMA as a pteroyldiglutamate transporter

Based on the above considerations and those that follow, we hypothesize that PSMA is expressed in prostate cancer for the importation of pteroyldiglutamate by clathrin-mediated endocytosis. This hypothesis is based, in part, on the established relationship between blood folate levels and the degree of prostate cancer aggressiveness [110]. Interestingly, the amount of circulating total folate increases with age in adults, as does the risk of prostate cancer [67,68,111]. In their first ten years, US males average 52 nM of total serum folate that subsequently falls to a nadir of 28 nM during their twenties and then rises linearly to a value of 55 nM for men in their eighth decade [111]. The slope of this linear increase as a function of dietary folate intake; the serum of men in their eighties consuming over 1000 μg folate per day contains an average 89 nM folate [111]. In the US, cereal grains are fortified with synthetic folic acid to mitigate the incidence of neural tube defects [112-114]. Dihydrofolate reductase catalyzes the reduction of folic acid to tetrahydrofolate. The activity of this enzyme is low in most tissues, including liver, and limits the metabolism of folic acid. Consequently, unmetabolized folic acid arises in blood when the amounts of ingested folic acid exceed 400 μg [115,116]. This overdosing is compounded in humans, which in addition to having less than 2% of the hepatic dihydrofolate reductase activity of rats, exhibit a five-fold variation in this activity [117]. Therefore, one unintended effect of folic acid fortification is the evolution of metabolized folic acid in the blood [68,118,119]. The amounts of metabolized folic acid parallel the aforementioned trends in total blood folate [111] and constitute approximately 4% of the total serum folate from 1 to 60 years of age [68]. At later ages, the unmetabolized folic concentrations can reach 13 nM equaling 10% of the serum total folate [68]. Obeid et al. [120] also reported that dosing elderly subjects with folic acid for 3 weeks increased serum folate levels from 0.08 to 15.5 nM (the subjects are German and therefore were not subjected to mandatory folic acid supplementation, hence the lower baseline levels than those reported for the US population [111] and cited above).

Folic acid is reduced by dihydrofolate reductase to tetrahydrofolate which forms a complex with thymidylate synthase to channel substrates for DNA synthesis [112]. The thymidylate synthase reaction produces dihydrofolate, a very potent inhibitor of methylene tetrahydrofolate reductase which shunts the folate pathway toward methionine biosynthesis and away from DNA metabolism. Dihydrofolate formation assures the otherwise toxic concentration of dihydrofolate, a very potent inhibitor of methylene tetrahydrofolate reductase. Thus, one unintended effect of folic acid fortification is the evolution of metabolized folic acid in the blood [68,118,119]. The amounts of metabolized folic acid parallel the aforementioned trends in total blood folate [111] and constitute approximately 4% of the total serum folate from 1 to 60 years of age [68]. At later ages, the unmetabolized folic concentrations can reach 13 nM equaling 10% of the serum total folate [68]. Obeid et al. [120] also reported that dosing elderly subjects with folic acid for 3 weeks increased serum folate levels from 0.08 to 15.5 nM (the subjects are German and therefore were not subjected to mandatory folic acid supplementation, hence the lower baseline levels than those reported for the US population [111] and cited above).

Folic acid is reduced by dihydrofolate reductase to tetrahydrofolate which forms a complex with thymidylate synthase to channel substrates for DNA synthesis [112]. The thymidylate synthase reaction produces dihydrofolate, a very potent inhibitor of methylene tetrahydrofolate reductase which shunts the folate pathway toward methionine biosynthesis and away from DNA metabolism. Dihydrofolate formation assures the otherwise toxic concentration of dihydrofolate, a very potent inhibitor of methylene tetrahydrofolate reductase.
Prostate cancer cells should thus have a growth advantage in the presence of a ready supply of folic acid and a means to import this folate. As noted earlier, the blood of older US males contains significant amounts of unmetabolized folic acid and other folates. The expression of PSMA in these men could therefore serve to import folic acid into the prostate and thereby promote DNA synthesis and anaplerosis in the resident neoplastic cells. In support of this hypothesis, PSMA facilitates folic acid uptake by neoplastic prostate cells induced to express PSMA [77]. Folic acid also blocks the uptake of the major circulating folate, methyltetrahydrofolate, by PSMA [123]. Thus, cells expressing both high levels of PSMA and dihydrofolate reductase may preferentially metabolize folic acid to support DNA synthesis (Fig. 2, reactions 1–3 and 6) rather than other aspects of one-carbon metabolism, as would be expected with methyltetrahydrofolate (Fig. 2, reaction 6).

Prostate PSMA in cancer

We hypothesize that PSMA plays an important role in glutamate and folate metabolism, but its function remains poorly understood. Notwithstanding its specific contributions to tumor development and progression, PSMA is an outstanding target for theranostic radiopharmaceuticals. In addition to its elevated expression in prostate cancer cells, PSMA is a type II transmembrane protein with glutamate-carboxypeptidase activity and a known substrate. Furthermore, upon ligand binding, PSMA is internalized via clathrin-coated pits and subsequent endocytosis, resulting in an effective transportation of the bound molecule into the cells. Since internalization leads to enhanced tumor uptake and retention, targeting PSMA is expected to result in high image quality and high doses of cytotoxic radiation absorbed by tumor cells. In Part 2 of this review, we summarize PSMA theranostic ligands in development and in clinical use.

Part 2: PSMA theranostic ligands

The concept of theranostics arose out of the potential to combine diagnostic and therapeutic capabilities in a single ligand. However, as the ideal pharmacokinetics for diagnostic applications (rapid accumulation in tumors, rapid clearance from non-target tissue, and no requirement for prolonged tumor retention) and therapeutic applications (high tumor uptake and prolonged retention and a biological half-life that is well-matched to physical half-life) differ, there has recently been a shift towards the use of one PSMA-targeting ligand for diagnosis and a separate ligand for evaluating tissue distribution, predicting dosimetry, and delivering therapeutic ionizing radiation. This review chooses to highlight PSMA-targeting ligands of the latter category due to their potential application in personalized medicine. However, we wish to highlight the fact that numerous PSMA-targeting ligands used exclusively for diagnostic purposes are under development. These are typically small molecule ligands with rapid tissue distribution and are reviewed elsewhere [124–128]. Ga-PSMA-11 [129] and F-DCFPyL [130] recently received FDA approval and are marketed as Ga68 PSMA-11 and Pylärify®, respectively. Both Ga-PSMA-11 and F-DCFPyL are cleared renally, leading to high bladder accumulation. As this can be disadvantageous for imaging metastases proximal to the prostate gland [131], new alternatives with more favorable clearance profiles are in various stages of clinical evaluation, including 18F-PSMA-1007 [132,133], 18F-CTT1057 [131], and 18F-JK-PSMA-7 [134,135]. Numerous single photon computed tomography (SPECT) agents for detecting prostate cancer by planar imaging have been developed in parallel to these PET agents. Among the SPECT agents to undergo preliminary clinical evaluation are 99mTc-MIP-1404 [83], 99mTc-MIP-1427 [136], 99mTc-PSMA-T4 [137], 99mTc-PSMA-I&S [138] and 99mTc-EDDA/HYNIC-PSMA [139]. As an alternative strategy, radiohybrid PSMA ligands incorporating fluorine-18/fluorine-19 and macrocyclic radiometal chelators have been developed as theranostic agents that exploit the superior imaging properties of fluorine-18 [140].

Among this new class of compounds, 18F-rhPSMA-7.3 has undergone preliminary clinical evaluation and is under FDA review [141].

Clinically advanced theranostic PSMA ligands

The first generation of PSMA-targeting agents were antibodies conjugated to radiometals for imaging or therapy. The 111In-labeled monoclonal antibody 7E11-C5.3 [142] (marketed as ProstaScint®) provided early validation of this PSMA targeted theranostic approach in advanced prostate cancer. Nevertheless, despite uptake in primary disease and metastatic lesions [142], 7E11-C5.3 targets an intracellular epitope on PSMA [89], restricting its ability to bind viable cells. Subsequent development of JS91, a humanized monoclonal antibody against the external domain of PSMA, stimulated renewed clinical investigation into PSMA-targeted imaging and therapy of progressive disease [143]. JS91 has undergone evaluation in men with metastatic castration-resistant prostate cancer (mCRPC) as an 111In-DOTA conjugate for SPECT imaging [144], an 89Zr-DFO conjugate for PET imaging [45], 90Y- [146] and 177Lu-DOTA [147] conjugates for targeted beta+-particle therapy, and an 225Ac-DOTA conjugate for targeted alpha-particle therapy [148]. Phase II clinical trials with 177Lu-JS91 have been completed, in which the response rate in treated patients, defined as ≥ 50% decrease in PSA, is 11% [147]. As a result of a circulation half-life in excess of 1 day [144], hematological toxicity is dose limiting [146]. Ongoing Phase I clinical trials with 225Ac-JS91 highlight response even in patients with prior 177Lu-JS91 PSMA-targeted radiotherapy, with no non-hematological grade 3/4 adverse events [149].

Small molecule alternatives to JS91 have proliferated following the identification of a high affinity heterodimeric urea pharmacophore for PSMA binding [150]. The chemical structures of leading examples of small molecule PSMA inhibitors are depicted in Fig. 3. In comparison to monoclonal antibodies, small molecules are excreted more rapidly, thereby reducing the likelihood of hematological toxicity. The majority of ligands to reach clinical trials incorporate a glutamate-urea-lysine (EuK) moiety for PSMA targeting. The first potential PSMA theranostic ligands were high-affinity small-molecule inhibitors of PSMA containing radioiodine, 123I-MIP-1072 and 123I-MIP-1095 [151]. The iodophenylurea derivative of EuK, MIP-1095, is a true theranostic ligand that shows clear delineation of tumor lesions when labeled with the positron-emitting radioisotope 124I and induces reductions in PSA, pain, and tumor volume in most patients when labeled with the beta-emitting radioisotope 131I [82]. The response rate reaches 70% following a single cycle of 131I-MIP-1095 therapy, although relapse is typical. Subsequent cycles do not appear to improve response, while xerostomia and hematological toxicities increase [93]. Xerostomia arises from physiologic uptake of the radioligand in the parotid and other salivary glands [82]. By contrast, hematological toxicities are likely due to the high energy beta-particles (E(β(max)) = 606 keV) emitted from 131I-MIP-1095 that accumulates in bone metastases. These particles travel a mean distance of 2.4 mm, which may allow escape from bone lesions into the neighboring marrow.

In contrast to 131I, 177Lu emits lower energy beta-particles (E(β(max)) = 497 keV) that travel a mean distance of 0.7 mm in soft tissue. Theranostic PSMA-targeting ligands bearing a macrocyclic chelator for complexation of 177Lu enable the favorable physical properties of this radionuclide to be harnessed for targeted radioligand therapy. The most widely studied ligand of this class, PSMA-617, incorporates a DOTA moiety for chelation of trivalent radiometals including 68Ga/67Ga [152, 153] and 177Lu [86]. In agreement with MIP-1095, 177Lu-PSMA-617 exhibits physiologic uptake in salivary and lacrimal glands, and kidneys. The dose to these structures is up to 10 times lower than that for 131I-MIP-1095 [154]. The efficacy of 177Lu-PSMA-617, now marketed as Pluvicto®, has been evaluated in multiple clinical centers across the world [99,155–160] and received FDA approval from the FDA in March 2022 for the treatment of men with mCRPC upon conclusion of the phase III VISION clinical trial [160]. The characteristics of the patients...
Representative clinical trial identifiers are reported where applicable.

Table 1

| Compound       | Clinical Status | Significant Attributes                                                                 | Significant Detrims                                                                 | Refs.   |
|----------------|-----------------|----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|---------|
| J591           | 68Zr: Phase I/II | • 95% accuracy for bone lesions                                                        | • 60% accuracy for soft tissue lesions                                               | 145     |
| 177Lu: Phase II | (NCT00195039)   | • Non-immunogenic                                                                      | • Dose-limiting, but reversible, hematological toxicity due to prolonged circulation | 147     |
|                |                 | • Response is proportional to PSMA expression                                           | • Modest therapeutic (any PSA decline) response compared to small molecule ligands   | 148, 149|
| PSMA-617       | 68Ga: Phase I   | • Effective in patients that received 177Lu-J591 as prior therapy                     | • Lower tumor penetration                                                           |         |
| 68Ga: First-in-Human |  | • No grade 3/4 hematological toxicity                                                  |                                                                                     |         |
| 68Sc: First-in-Human |  | • High sensitivity and specificity (> 87%)                                             |                                                                                     |         |
| 66Cu: First-in-Human |  | • Tumor SUV is similar to 68Ga-PSMA-11                                               | • Slower renal clearance than 68Ga-PSMA-11                                           | 152,153 |
|                |                 | • Tumor imaging possible up to 18 h, providing better match for 177Lu dosimetry calculations | • Intense salivary gland uptake                                                      |         |
|                |                 | • Late stage PET imaging (2 h < t < 22 h) is possible                                  | • Dose to kidneys is 2x higher than 68Ga-PSMA-617                                     | 212     |
| 177Lu: FDA Approved (2022) |  | • Response rate is 45–55% with no grade 3/4 toxicities                                 | • No additional lesions are evident at later imaging time points                     | 203     |
| 225Ac: Phase I/II | (NCT04506567)  | • Response rate > 60% even in patients refractory to 177Lu-PSMA-617                   | • Radiation dose is higher than 68Ga ligands                                        |         |
|                |                 | • No hematological toxicity                                                           | • Limited in vivo stability                                                          |         |
| PSMA-617       | 225Ac: Phase I  | • Lower whole body 1/2 than 177Lu-PSMA-617                                             | • Relapse is frequent                                                                | 154–162 |
| 225Ac: First-in-Human |  | • Lower dose to parotid, submandibular, and lacrimal glands than 177Lu-PSMA-617      | • Dose-dependent xerostomia                                                          | 94,95,163,164 |
| 124I: MIP-1095 | Phase II (NCT03939689) | • Tumor response achieved in patients refractory to 177Lu-PSMA-617                    | • Delayed nephrotoxicity possible                                                    |         |
| 177Lu-PSMA-ALB-56 | First-in-Human | • >65% response to a single dose                                                      | • Grade 1/2 xerostomia                                                               | 170,171 |
| 177Lu-EB-PSMA-617 | Phase I (NCT03403595) | • Higher dose in tumor lesions than 177Lu-PSMA-617 and 177Lu-PSMA-617                 | • Dose-limiting xerostomia                                                           | 82, 93  |
|                |                 | • Lower kidney dose than other albumin-binding ligands                                 | • kidney and red marrow doses are higher than 177Lu-PSMA-617                         | 192     |
|                |                 | • Comparable response to 177Lu-PSMA-617 at lower administered dose                    | • Dose to salivary glands is comparable to 177Lu-PSMA-617                           | 190, 191|
|                |                 | • Substantially higher salivary gland dose than 177Lu-PSMA-617                       | • Dose-dependent hematological toxicity                                              |         |

Radiohalogened PSMA inhibitors for theranostics

The identification of a number of potent small molecule inhibitors of PSMA containing iodophenyl [172], iodobenzyl [173] or iodobenzenamide groups [85,174] has stimulated the development of alternatives to MIP-1095 for PSMA-targeted theranostics. Although comparisons between molecules evaluated in different xenograft models should be performed with caution, it appears that the tumor-to-kidney ratio of these radiohalogenated ligands is generally lower than that of MIP-1095 [172–174]. Consequently, although Auger electron-emitting 125I-DClBzL and α-particle-emitting 211At-DClBzL are efficacious in micrometastatic prostate cancer animal models, the therapeutic effect was observed only at doses associated with delayed renal toxicity [175, 176]. Attempts to improve the pharmacokinetics of 211At-labeled compounds for targeted alpha particle therapy identified one compound, [211At]HS-549, with superior tumor-to-ratio indices in mice, but this is included in these studies vary and are reviewed elsewhere [161]. These studies report a rate of 45–55% following multiple cycles of 177Lu-PSMA-617 [161,162], with median overall survival of 14 months [99,162] and progression-free survival of 8 months [162]. Mild or transient xerostomia was reported in approximately 10% of patients [98], and increased at higher doses [162]. This toxicity became dose-limiting in patients undergoing targeted alpha therapy (TAT) with 225Ac-PSMA-617 [94,163]. Notwithstanding elevated toxicity in salivary and parotid glands, the response rate of patients undergoing single dose TAT exceeds 60% [163,164], with the majority of these patients experiencing a PSA decline > 80%, and responses are observed even in patients who are refractory to β-particle therapy [94] or who have brain metastases [165]. Dose de-escalation appears to reduce xerostomia in some patients without compromising therapeutic efficacy [164]. The average progression-free survival is 9 months, which compares favorably to treatment of earlier stage disease [163].
likely due to extensive dehalogenation of this compound which renders it unattractive for clinical translation [177]. Even where the kidney absorbed dose is lower than that observed with MIP-1095, as is the case for MIP-1072, accumulation of the ligand in tumors is also significantly decreased [151], and further clinical evaluation is not warranted.

One exception to this trend is the iodophenyl ligand, RPS-027 [85]. This small molecule dually targets both PSMA and serum albumin to increase tumor accumulation as a function of increased plasma residence time. As a result, the tumor-to-kidney ratio in preclinical models is superior to that of other radiohalogenated PSMA ligands. RPS-027 validated the strategy of incorporating albumin-binding moieties into PSMA-binding structures to increase the therapeutic index. Despite promising pharmacokinetic profile, the major limitation of RPS-027 and its structural analogues is the inability to independently modify PSMA affinity and albumin affinity. Further optimization of this class of molecules was not possible.

**Albumin-binding PSMA ligands for theranostics**

Next generation PSMA theranostic ligands have separated the albumin-binding moiety and the PSMA-binding moiety in chemical space, often using a linker group to which a macrocyclic chelator is conjugated. This modular approach has allowed the relative affinities for PSMA and serum albumin to be fine-tuned. The advantages to such an approach are evident in 177Lu-RPS-063, which delivers 5 times greater dose to tumors than 177Lu-PSMA-617 in an LNCap xenograft tumor model [178]. Notwithstanding the high PSMA affinity and the affinity for serum albumin, clearance from blood is faster than expected, and clearance of activity from tumors is evident after 4 h post injection. Extended tumor loading and retention is achieved by using 177Lu-RPS-072, in which the high affinity 4-(4-iodophenyl)butanoic acid (IPBA) albumin binding group [179] increases affinity for serum albumin, with a corresponding delay in the clearance from blood [180]. In concert with an increasing dose to LNCap tumors, 1.5 times greater than 177Lu-RPS-063 over 96 h, is a significant reduction in kidney retention. The resulting tumor-to-kidney ratio compares favorably to other ligands evaluated in an LNCap xenograft model. Clearance from blood fits an exponential decay function with a half-life of 14.6 h [180]. By comparison, pharmacokinetic modeling in human patients has shown the plasma clearance of 177Lu-J591 to be an exponential decay function with a half-life of 39.1 ± 13.3 h [181]. These data suggest that enhanced albumin binding is unlikely to lead to dose-limiting hematologic toxicity and support the application of this platform to TAT. RPS-074 [182] is a structural analogue of RPS-072 that employs the macrocra [183] macrocyclic chelator for 225Ac chelation. A complete tumor response with no overt toxicity was observed in an LNCap xenograft model following a single dose of 148 kBq 225Ac-RPS-074, with a single dose of 74 kBq allowing tumor control over 6 weeks [182].

As an alternative to the modular trifunctional constructs, many groups have explored albumin-binding derivatives of PSMA-617. These compounds incorporate a range of albumin binding moieties, including the higher affinity IPBA [184,185], 4-(4-chlorophenyl)butyric acid [186], ibuprofen [187,188], and Evans blue (EB) [189] groups, and the moderate affinity p-(tolyl)butanoic acid [87] moiety. Activity in PC3-PiP xenograft tumors is high and sustained following injection of these ligands, leading to an area under the curve (AUC) that is 2–5 times greater than for 177Lu-PSMA-617 in the same model [87,184,186,189]. This trend is also observed in an LNCaP xenograft model [185,186]. This significant because the expression level of PSMA in PC3-PiP cells is 10-fold higher than in LNCaP cells [175] and likely is substantially higher than expression in clinical samples. Activity in the kidney is also substantially higher and persists up to 192 h post injection. One exception is 177Lu-PSMA-ALB-56, which exhibits a steeper clearance curve [87]. PSMA-ALB-56 incorporates a lower affinity albumin binding group, although the relationship between serum albumin binding and kidney clearance requires further study. Tumor control is accomplished for 5–9 weeks following a single dose of the 177Lu-labeled ligand with no apparent toxicity [189]. This translates to survival benefits in xenograft mouse models. Encouragingly, preliminary clinical head-to-head evaluation of these 177Lu-labeled albumin-binding PSMA ligands against 177Lu-PSMA-617 indicates 2–3 times greater absorbed dose in tumors [190] and translates to adequate tumor control without grade 3 or 4 toxicities [191]. Kidney [190,192] and red marrow [191,192] doses are also increased, however. The longer-term implications of these off-target doses are under investigation.

The EB group has also been used to increase the circulation time of a small molecule incorporating a glutamate-urea-cysteine moiety for PSMA binding rather than a glutamate-urea-lysine moiety [193]. Despite comparable affinity for PSMA, uptake of 186Y-DOTA-EB-MCG in PC3-PiP xenograft tumors is reduced relative to that observed with 86Y-EB-PSMA-617 [193]. A construct conjugating a phosphoramidate-based PSMA binding group and IPBA to the DOTA macrocycle obtained by click chemistry slowly clears from the blood, leading to progressive tumor loading [194]. Although accumulation of this molecule, 177Lu-CTT1403, in PC3-PiP tumors is sustained beyond 120-h post injection, activity in the kidney is high at all time-points. As a result, the tumor-to-kidney ratio does not exceed 1 [195], and renal toxicity will likely limit the dose that can be safely administered.

It is argued that conjugation of an albumin binding group to a PSMA targeting ligand decreases the rate of renal excretion due to a reduction in receptor-mediated kidney uptake [194], perhaps as a consequence of masking the highly anionic charge of the molecule. Early preclinical experience with albumin-binding PSMA ligands is inconclusive in this regard: some compounds with high albumin binding exhibit relatively low kidney doses (e.g., 177Lu-RPS-072, 177Lu-PSMA-ALB-56, 177Lu-I-but-DAB-PSMA), while others demonstrate prolonged kidney retention. The consequences of renal retention on nephrotoxicity arising from targeted radioligand therapy have yet to be determined, but this activity can be displaced by administration of 2-(phosphonomethyl)pentane-dioic acid (2-PMPA) [84], a potent PSMA inhibitor [196], or non-radiolabeled PSMA-11 [197], a small molecule PSMA inhibitor [198,199] that is FDA-approved for prostate cancer imaging when labeled with 68Ga. Nor is it established whether enhanced albumin binding will restrict physiological uptake of radiolabeled PSMA ligands in submandibular, parotid, and lacrimal glands. Assessment of ligand uptake in these tissues in preclinical murine models is challenging, in part because the rodent glands are substantially different from those of humans. Clinical data are scarce but conflicting; increased circulation time of [18F]DCBFC [200] relative to [18F]DCFPy [130] corresponds with decreased gland uptake, but accumulation of 177Lu-Eb-PSMA-617 in these glands is more pronounced than that obtained with 177Lu-P-PSMA-617 [190], and the albumin-binding compound 177Lu-L14 accumulates in salivary glands to a greater extent than analogous PSMA ligands with faster blood clearance in a preclinical model [201]. Further evaluation of albumin-binding PSMA ligands in prostate cancer patients may resolve this outstanding question.

**Application of novel radionuclides, radioisotopes, and chelators to PSMA theranostics**

In tandem with the development of new PSMA targeting ligands is the use of emerging radionuclides for imaging and therapy and the development of novel chelators to complex these metals. Radioisotopes of copper are re-emerging for theranostic application in prostate cancer. Copper-64 (t1/2 = 12.7 h, β− = 18%, β+ = 39%) is itself a theranostic ligand, and also forms a unique theranostic pair with 66Cu (t1/2 = 2.58 d, β− = 100%). Preliminary evaluation of 64Cu-PSMA-617 in prostate cancer patients revealed accumulation of activity in the liver, indicating insufficient complex stability [202,203]. Consequently, PSMA targeting molecules bearing chelators that complex copper with greater stability are in preclinical development. Early examples of these chelators cleared rapidly from circulation, leading to low uptake in xenograft tumors.
The 43/44/47Sc theranostic triad also holds promise in clinical management of prostate cancer. The physical properties of 43Sc (t1/2 = 3.89 h, β− = 88%) and 44Sc (t1/2 = 4.04 h, β− = 95%) and 47Sc (t1/2 = 3.35 d, β− = 100%) are better suited for radioligands with longer circulation times, such as albumin-binding PSMA ligands, than 68Ga [211]. Of the two, positron-emitting isotopes of scandium, 47Sc is preferred for clinical application because 47Sc has a high energy gamma emission that increases radiation dose [212]. Initial studies of 47Sc-PSMA-617 confirm PSMA-specific uptake and high complex stability with distribution kinetics similar to 177Lu-PSMA-617 [213,214]. First-in-human evaluations suggest that dosimetry is favorable to 177Lu-PSMA-617 in the context of pre-therapy planning [213]. However, chelation of Sc3+ by DOTA requires prolonged heating at 95 °C. Consequently, new chelators have been introduced that complex Sc3+ rapidly and under mild conditions. One such example is picaca, a small bifunctional heterocyclic chelator with a picolinate arm that forms highly stable complexes with Sc3+ and Lu3+ [215]. A single dose of 177Lu-picaca-Alb53-PSMA inhibited tumor growth for more than 3 weeks in a preclinical prostate cancer model [216]. Greater efficacy may be possible with a multiple dose regimen, although the effect of dose fractionation on off-target toxicity is yet to be established.

As new radiometal β-emitters for PSMA-targeted radioligand therapy, such as 47Sc [216,217], 64Cu [207,208,210], and 68Ga [218], and α-emitters, such as 182Wb [219], 192Ir [220,221], 225Ac [222], and 225Ac become more widely available, the value of bifunctional chelators capable of rapidly complexing metal ions with high in vivo stability will continue to grow. This is particularly true for TAT, in which release of the radiometal from the chelator can lead to dose-limiting toxicity as a result of undesirable accumulation of the free metal in off-target tissue. Despite its widespread use, the DOTA macrocycle is not optimal for larger α-emitters such as actinium-225. This is evidenced by the decrease in lanthanide-DOTA complex stability constant with increasing lanthanide ion diameter [223]. The lack of stability is likely a product of both small ring size and the distance between the metal ion and the oxygen donor atoms of the acetic acid pendant arms [224]. To address these limitations, larger 18-membered macrocycles such as macropa [183], crown [225], py-macrodip [226], and mcp-D-click [227] have recently been introduced to chelate 225Ac3+ or 212Bi3+ with exceptionally high stability. An alternative approach has been to explore acyclic hydroxypropyridonate (HOP) or picolinic acid chelators. To date, these chelators have been used to complex Th4+ with reasonable stability [228,229]. The development of these novel chelators, along with those reported for Sc3+ [215,217], Cu2+ [208], Lu3+ [215], and Pb2+ [230], represents an exciting development in PSMA theranostics. Nevertheless, many of these chelators have yet to be prepared and tested as bifunctional conjugates, and their incorporation into high affinity PSMA targeting ligands remains to be demonstrated.

Accumulation of PSMA ligands in the major salivary glands represent a major barrier for targeted radiotherapy of prostate cancer. This accumulation is comparable to the sequestration of PSMA ligands within the diseased prostate and results in reversible damage to the glands [94,95]. These glands produce saliva and loss of this production significantly impacts the quality-of-life of patients receiving targeted radiotherapy with certain PSMA ligands [231,232]. Early, unsuccessful, strategies for reducing sialotoxicity targeted inflammation and included approaches such as external cooling of the glands with ice packs [233,234], and sialendoscopy with steroid injection [235]. These experiences confirmed that xerostomia was not caused by inflammation alone. More promising results were obtained with the intraparenchymal injection of botulinum toxin, which significantly reduced PSMA ligand uptake in the treated parotid gland [236]. More recent studies have shown that higher doses of this toxin are tolerated [237]. However, this approach is based on the disruption of the neural control of the treated gland and so is limited to the treated glands only and may cause extended dysfunction of gland activity.

The mixed results of these initial experiences have stimulated interest in understanding and perturbing the mechanism of uptake and sequestration of PSMA ligands by salivary glands. Aside from the PSMA specific antibodies, J591 and 7E11-C5.3, most PSMA ligands are small molecule anions due in part for the requirement of a glutamyl residue for binding the PSMA active site. Many of these ligands therefore include a glutamate moiety and numerous groups have sought to displace these ligands using glutamate [238–240]. Intraperitoneal injection of monosodium glutamate (MSG) reduced salivary gland and kidney uptake of 68Ga-PSMA-11 in mice without significantly altering tumor uptake [238]. Although the rationale for the approach is the displacement of 68Ga-PSMA-11 by glutamate, this mechanism is not the most likely explanation for the observed reductions in salivary gland and kidney retention. Glutamate is rapidly metabolized in the gut upon first pass [241], meaning that the mass available for 68Ga-PSMA-11 antagonism in kidneys and salivary glands is substantially reduced. By contrast, the mass of sodium administered, > 45 mg/kg at the effective dose of MSG, translates to an increase in blood sodium concentration of > 25 mM. Physiological sodium concentration is highly regulated, and hypernatremia on this scale is likely to induce thirst, changes in sympathetic nerve activity, release of antidiuretic hormones [242], and reduced salivary gland flow rates [243] to restore sodium concentration. Notwithstanding these observations, co-administration of MSG is being investigated in two clinical trials designed to reduce uptake of 68Ga-P-PSMA-11 (NCT04282824) or 18F-DCFPPyL (NCT03693742) uptake for imaging.

We wish to propose the process by which organic anions are transported from blood and concentrated in saliva as an alternative target for intervention. Daily saliva production varies between 0.5 and 1.5 liters in humans and is facilitated by the transepithelial transport of ions [244]. A comprehensive account of saliva and its constituents is beyond the scope of this review (instead see [244,245]), instead we will discuss two anions: thiocyanate, [SCN]− and nitrate, NO3−, concentrated in saliva—and by extension within the salivary glands—to both indicate the unique actions of these glands and a possible means by which they sequester PSMA ligands.

[SCN]− arises from the actions of rhodanese (EC 2.8.1.1) on cyanide (CN−), which is released during the catabolism of many foods or inhaled as a component of combustible tobacco and marijuana [246,247]. In addition to being significantly less toxic than CN−, [SCN]− is the preferred substrate for myeloperoxidase (EC 1.11.2.2) and salivary peroxidase (EC 1.11.1.7), both of which exist in saliva [248]. These enzymes catalyze the oxidation of halides and [SCN]− to their respective hypohalous acids (e.g., hypochlorous acid and hypoiodous acid) as a part of the oral antimicrobial defense [249–251]. [SCN]− is

T.M. Jeitner et al.
remarkably concentrated in saliva relative to serum (1 mM vs. 34 μM [252,253], and reaching 2.6 mM in smokers [253]). NO₃ is similarly concentrated by the salivary glands from serum for secretion as a salivary anion. The concentrations of NO₂ in blood and saliva are 38 μM and 435 μM, respectively [254,255]. Salivary glands act to recover 25% of the NO₂ in blood and return it to the cardiovascular system to support the production of nitric oxide, is a critical modulator of vascular relaxation [256]. Salivary NO3 concentrations vary as a function of age and diet and can be increased as much as 100-fold relative to blood NO3 levels by dietary supplementation [256,257]. Thus, salivary glands act to sequester anions from the blood and in some cases, such as [SCN] and NO₃, concentrate these for secretion into saliva to support oral and general health.

Sialin is a versatile anion transporter expressed in salivary glands [258] that transports glutamate, NO₃, and other anions from blood to saliva. We hypothesize that salivary epithelium sequesters the PSMA ligands by uptake through the sialin anion/H⁺ symporter on the basolateral side of these cells but is not able to secrete the ligands into the saliva at the apical side. This imbalance between the ingress and egress of PSMA ligands results in their accumulation. In support of this hypothesis, sialin transports NAAG and a variety of glutamate containing xenobiotics, as well as NO₃ and glutamate, into epithelial cells [259–261]. Salivary glands also express the most sialin in mammals [258,261] whereas the other conduit for PSMA ligand uptake, PSMA, is expressed at very low levels in these glands [10,36,89]. Moreover, PSMA expression is restricted to intercalated epithelium of these glands [36]. Intercalated epithelial cells constitute a relatively minor portion of salivary gland and explains the apparent absence of PSMA in some studies [19,[9],[262]. The role of PSMA in the intercalated epithelia cells is not known, but interestingly these cells give rise to neoplasias just as the PSMA expressing cells in the prostate do [263,264].

Uptake of small molecule PSMA ligands by salivary sialin/H⁺ symporters suggest the possibility of antagonizing this uptake and sparing the salivary glands during targeted radiotherapy. Possible antagonists include sialin transport inhibitors developed by Gasnier and colleagues [259,265], oral poly-glutamate tablets [239,240], and anions concentrated by the salivary glands like NO₃ and [SCN]⁻. The advantages of the NO₃ as salivary PSMA ligand antagonists include the availability of numerous medically approved formulations this anion, and the fact that NO₃ is radioprotective [257]. Humans also tolerate [SCN]⁻ well (as indicated by smokers) and this compound can act as an antioxidant [266–268]. Intriguingly, a recent study in patients receiving radiotherapy for oropharyngeal cancer identified an inverse correlation between smoking and the grade of xerostomia [269], and these patients are likely to have had high [SCN]⁻ concentrations in their blood. We are not aware of meta-analyses of prostate cancer patients receiving PSMA radioligand therapy that investigate this relationship. Additionally, radiotherapy for nasopharyngeal carcinoma results in long term and significant decrements in salivary NO₃ and [SCN]⁻ levels [270]. Thus, augmenting the salivary concentrations of these anions, prior to targeted radiotherapy, may produce salutary effects in addition to mitigating salivary PSMA ligand uptake [257]. Testing these possibilities would be best done using miniature pigs, which unlike rodents, have parotid glands that resemble those of humans [271,272].

Conclusions and future directions

Over the past decade, the theranostic paradigm has driven ligand development for PSMA-targeted imaging and therapy. This effort has seen the translation of multiple PSMA-targeting ligands for imaging and radioligand therapy of mCRPC. Given the expression of PSMA is non-prostatic neoplasms, there may also be an opportunity for PSMA-targeted imaging and therapy in non-prostatic disease [273]. If this proves to be the case, the clinical experience with PSMA theranostics in mCRPC patients will be invaluable. The impact of ligands such as J591, PSMA-617, and PSMA-I&T to extending life with quality is already considerable, and these ligands have also provided crucial information about tissue distribution and off-target toxicity. Consequently, emerging ligands complexing new radionuclides are poised to address the limitations of the first generation theranostic compounds. One of the major limitations is salivary gland toxicity, which is prevalent and may even be irreversible in TAT. The mechanism of uptake of small molecule PSMA ligands in the salivary glands is not yet known, but strategies for their displacement are emerging. It remains to be seen if these strategies are effective in reducing long-term salivary gland toxicity.

As clinical experience with TAT continues to grow, it will be necessary to address the challenges of performing dosimetry for new PSMA ligands. The versatility of DOTA enables dosimetry for 225Ac-labeled constructs to be estimated on the basis of the tissue distribution of the 177Lu-labeled ligand. However, in the absence of stable isotopes of actinium, it is often difficult to determine whether the PSMA affinity of the 225Ac-labeled and 177Lu-labeled analogues are identical. As a result, there is inherent uncertainty in these estimates of dosimetry. New chelating moieties that chelate Ac³⁺ with greater stability may transform TAT and increase the therapeutic index of the ligands to which they are conjugated. However, these chelating moieties may be highly selective for Ac³⁺, thereby preventing the use of chemically identical ligands labeled with radiometals such as ¹¹¹In³⁺ and ¹⁷⁷Lu³⁺ for estimating dosimetry. Substitution of another chelating moiety for the purposes of binding smaller radiometals might influence the tissue distribution of the ligand, adding further uncertainty to the dosimetry calculations. New strategies will need to be developed in order to fully capitalize on the potential of PSMA TAT.

In addition to highlighting the challenges of producing and assessing the PSMA ligands as theranostic agents, we have sought to note areas where biology might aid in these efforts. Most, if not all, ligands are based on compounds that block the catalytic activity of PSMA – and more to the point – the hydrolysis of N-acetyl aspartylglutamate. This strategy favors the regulation of N-acetyl-a-linked dipeptidase. The actions of PSMA in prostate cancer may be to endocytose folates and therefore rely on different molecular interactions than those required to hydrolyze peptide linkages. Given that the efficacy of PSMA ligands as prostate cancer theranostics relies on the endocytosis of these compounds, a better understanding of this process is likely to lead to better therapeutics. This effort will also be aided by identifying the ligands for PSMA in prostate cancer, as these compounds will serve as parent compounds of future ligands. Identifying these ligands also has the potential of identifying potential risk factors for this disease. Since one of the candidates for the endogenous prostatic PSMA ligand is folic acid, these studies are of interest not only to those of us wishing to eliminate prostate cancer, but a broader community whose purvey includes public health and policy.

CRediT authorship contribution statement

Thomas M. Jeitner: Conceptualization, Writing – original draft, Writing – review & editing. John W. Babich: Conceptualization, Writing – original draft, Writing – review & editing. James M. Kelly: Conceptualization, Writing – original draft, Writing – review & editing, Resources.

Declaration of Competing Interest

J.W. Babich and J.M. Kelly hold intellectual property rights to compounds described in this manuscript. J.W. Babich and J.M. Kelly also hold equity in Ratio Therapeutics, a licensor of intellectual property related to compounds described in this manuscript. T.M. Jeitner has no declarations of interest to disclose.

Acknowledgments

Mr. Brendan Murphy and Prof. John T. Pinto and Arthur J.L. Cooper...
are thanked for their careful editing of the manuscript, as well as their insightful suggestions.

References

[1] C.H. Halsted, I.H. Ling, R. Luthi-Carter, J.A. Villanueva, J.M. Gardner, J.T. Coyle, Folylpoly-gamma-glutamate carboxypeptidase from pig jejunum. Molecular characterization and relation to glutamate carboxypeptidase II, J. Biol. Chem. 273 (32) (1998) 20417–20424. Aug 7.

[2] R. Luthi-Carter, A.K. Barczak, H. Speno, J.T. Coyle, Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase), J. Pharmacol. Exp. Ther. 286 (2) (1998) 1020–1025. Aug.

[3] G.L. Wright, C. Haley, M.L. Beckett, P.F. Schellhammer, Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues, Urol. Oncol. 11 (4) (2014) 118–28. Feb.

[4] A.M. Reiseiner, C.H. Halsted, Human jejunal brush border folate conjugate: Characteristics and inhibition by salicylaspartylfufimide, Biochim. Biophys. Acta (BBA) Enzymol. 659 (1) (1981) 62–69. May.

[5] B.H. Maraj, J.P. Leek, M. Karayi, M. Ali, N.J. Lench, A.F. Markham, Detailed genetic mapping around a putative prostate-specific membrane antigen locus on human chromosome 11p11.2, Cytogenet. Cell Genet. 81 (1) (1998) 3–9.

[6] D.S. O’Keeffe, S.L. Do, D.J. Bacch, H. Hiruguchi, Y. Luo, C.T. Powell, et al., Detailed genetic mapping around a prostate-specific membrane antigen gene, Biochim. Biophys. Acta (BBA) Gene Struct. Expr. 1443 (1–2) (1998) 113–127. Nov.

[7] J. Leek, N. Lench, B. Maraj, A. Bailey, L.M. Carr, S. Andersen, et al., Prostate-specific membrane antigen: evidence for the existence of a second related human gene, Br. J. Cancer 72 (3) (1995) 583–588. Sep.

[8] C. Barinka, P. Sácha, J. Sklenar, P. Man, K. Bezouzka, B.S. Bluscher, et al., Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity, Protein Sci. 13 (6) (2004) 1627–1635. Jun.

[9] T. Williams, R. Kole, Analysis of prostate-specific membrane antigen splice variants in LNCAp cells, Oligonucleotides 16 (2) (2006) 186–195.

[10] R.S. Israeli, C.T. Powell, W.R. Fair, W.D. Heston, Molecular cloning of a prostate-specific membrane antigen, Cancer Res. 53 (2) (1993) 227–230. Jan 15.

[11] P. Milcovich, C. Barinka, J. Tykvart, P. Sácha, J. Konvalinka, Prostate-specific membrane antigen and its truncated form PSM, Prostate 69 (5) (2009) 471–479. Apr 1.

[12] X. Zhang, C. Morrissey, S. Sun, M. Ketchandji, P.S. Nelson, L.D. True, et al., Androgen receptor variants occur frequently in castration resistant prostate cancer metastases, Urol Oncol 6 (11) (2011) e27970. Nov 17.

[13] S. Diviya, S.M. Naubahd, A. Addagatta, P.V.L.N. Murthy, C.R. Reddy, R. Diguamarti, et al., Paradoxical role of C1561T glutamate carboxypeptidase II (GCPID) genetic polymorphism in altering disease susceptibility, Gene 497 (2012) 273–279. Apr 15.

[14] S.F. Autschl, T.L. Madden, A.A. Schaffer, J. Zhang, Z. Zhang, W. Miller, et al., Gapped BLAST and PSI-BLAST: a new generation of protein database search programs, Nucleic Acids Res. 25 (17) (1997) 3389–3402. Sep 1.

[15] R. Luthi-Carter, U.C. Sanger, A.K. Barczak, J.T. Coyle, Isolation and expression of a rat brain CDNA encoding glutamate carboxypeptidase II, Proc. Natl. Acad. Sci. USA 95 (6) (1998) 3215–3220. Mar 17.

[16] M.B. Robinson, R.D. Blakely, M.B. Robinson, R.C. Thompson, J.T. Coyle, Hydrolysis of the brain dipeptide N-acetyl-aspartyl-glutamate, J. Neurochem. 65 (1) (2004) 279–282. Nov 22.

[17] T.D. Schmitz, S. Tseke, R.L. Vessella, L.D. True, B.A. Zakrzewska, J. Sciarretta, et al., Expression of prostate-specific membrane antigen in breast cancer, Breast Cancer Res. 19 (1) (2017) 77. Mar.

[18] M.B. Robinson, R.D. Blakely, M.B. Robinson, R.C. Thompson, J.T. Coyle, Hydrolysis of the brain dipeptide N-acetyl-aspartyl-glutamate, J. Neurochem. 65 (1) (2004) 279–282. Nov 22.

[19] L. Corral, K. Hlouchova, P. Sácha, P. Kordula, F. Hlavatka, J. Zitny, et al., Expression and tissue expression and enzymologic characterization of human prostate specific membrane antigen and its rat and pig orthologs, Prostate 68 (2) (2008) 171–182. Feb 1.

[20] J. Zhang, C. Morrissey, S. Sun, M. Ketchandji, P.S. Nelson, L.D. True, et al., Androgen receptor variants occur frequently in castration resistant prostate cancer metastases, Urol Oncol 6 (11) (2011) e27970. Nov 17.

[21] X. Zhang, C. Morrissey, S. Sun, M. Ketchandji, P.S. Nelson, L.D. True, et al., Androgen receptor variants occur frequently in castration resistant prostate cancer metastases, Urol Oncol 6 (11) (2011) e27970. Nov 17.

[22] S. Diviya, S.M. Naubahd, A. Addagatta, P.V.L.N. Murthy, C.R. Reddy, R. Diguamarti, et al., Paradoxical role of C1561T glutamate carboxypeptidase II (GCPID) genetic polymorphism in altering disease susceptibility, Gene 497 (2012) 273–279. Apr 15.

[23] S.F. Autschl, T.L. Madden, A.A. Schaffer, J. Zhang, Z. Zhang, W. Miller, et al., Gapped BLAST and PSI-BLAST: a new generation of protein database search programs, Nucleic Acids Res. 25 (17) (1997) 3389–3402. Sep 1.

[24] R. Luthi-Carter, U.C. Sanger, A.K. Barczak, J.T. Coyle, Isolation and expression of a rat brain CDNA encoding glutamate carboxypeptidase II, Proc. Natl. Acad. Sci. USA 95 (6) (1998) 3215–3220. Mar 17.

[25] M.B. Robinson, R.D. Blakely, M.B. Robinson, R.C. Thompson, J.T. Coyle, Hydrolysis of the brain dipeptide N-acetyl-aspartyl-glutamate, J. Neurochem. 65 (1) (2004) 279–282. Nov 22.

[26] T.D. Schmitz, S. Tseke, R.L. Vessella, L.D. True, B.A. Zakrzewska, J. Sciarretta, et al., Expression of prostate-specific membrane antigen in breast cancer, Breast Cancer Res. 19 (1) (2017) 77. Mar.

[27] M.B. Robinson, R.D. Blakely, M.B. Robinson, R.C. Thompson, J.T. Coyle, Hydrolysis of the brain dipeptide N-acetyl-aspartyl-glutamate, J. Neurochem. 65 (1) (2004) 279–282. Nov 22.

[28] L. Corral, K. Hlouchova, P. Sácha, P. Kordula, F. Hlavatka, J. Zitny, et al., Expression and tissue expression and enzymologic characterization of human prostate specific membrane antigen and its rat and pig orthologs, Prostate 68 (2) (2008) 171–182. Feb 1.
[52] K.A. Rahn, B.S. Shusser, A.I. Kaplin, Glutamate in CNS neurodegeneration and cognition and its regulation by GCPII inhibition, Curr. Med. Chem. 19 (9) (2012) 1355–1365.
[53] J.J. Vornov, D. Peters, M. Nedelcovych, K. Hollinger, R. Rais, B.S. Shusser, Looking for drugs in all the wrong places: use of GCPII inhibitors outside the brain, Neurochem. Res. 45 (6) (2020) 1256–1267. Jun.
[54] L.L. Jin, M. Wanger, T.C. Lightbourne, T. Czakay, N. Ynin, A.F. Arnsten, et al., mGlur2 versus mGlur3 metabolic glutamate receptors in primate dorsolateral prefrontal cortex: postynaptic mGlur3 strengthens working memory networks, Cereb. Cortex 28 (3) (2018) 974–987. Mar. 1.
[55] K.R. Hollinger, A. Sharma, C. Tallon, L. Lovell, A.G. Thomas, X. Zhu, et al., Dendrimer-2PMPA selectively blocks upregulated microglial GCPII activity and improves cognition in a mouse model of multiple sclerosis, Nanoletters 6 (2) (2006) 126–132. Feb. 1.
[56] C.F. Zink, P.B. Barker, A. Sawa, D.R. Weinberger, M. Wang, H. Quillian, et al., Association of missense mutation in FOLH1 with decreased NAAG levels and impaired working memory circuitry and cognition, Am. J. Psychiatry 177 (12) (2020) 1129–1139. Dec. 1.
[57] D. Datta, S.N. Leslie, E. Woo, N. Amancharla, A. Elmanysz, M. Lepe, et al., Glutamate carboxypeptidase II in aging rat prefrontal cortex impacts working memory performance, Front. Aging Neurosci. 13 (2021), 760270. Nov. 15.
[58] U.V. Berger, R.E. Carter, J.T. Coyle, The immunocytochemical localization of N-acetylaspartyl glutamate, its hydrolyzing enzyme NAALADase, and the NMDAR1 receptor at a vertebral neuropeural junction, Neuroscience 64 (4) (1995) 847–850. Feb.
[59] P. Marmori, T. Shusher, G. Gavilletti, Tissue distribution of glutamate carboxypeptidase II (GCPII) with a focus on the central and peripheral nervous system, Curr. Med. Chem. 19 (9) (2012) 1277–1281.
[60] Z. Zhang, B. Bassam, A.G. Thomas, M. Williams, J. Liu, E. Nance, et al., Maternal GCPII inhibition leads to impaired glutamate metabolism and up-regulation of glutamate carboxypeptidase II in active microglia in the fetal/newborn rabbit brain, Neurobiol. Dis. 94 (2016) 116–128. Oct.
[61] O. Artrega Cabeza, Z. Zhang, E. Smith Khoury, R.A. Sheldon, A. Sharma, F. Zhang, et al., Neuroprotective effects of a dendrimer-based glutamate carboxypeptidase inhibitor on superoxide dismutase transgenic mice after neonatal hypoxic-ischemic brain injury, Neurobiol. Dis. 148 (2021) 105201. Jan.
[62] H. Li, D.A. Gah, B. Ahn, J. Kim, J. Cho, A. Kim, et al., Blocking glutamate carboxypeptidase II overexpression in activated microglia could improve cognitive function of transgenic mice for Alzheimer’s disease, Translational Oncology 22 (2) (2019) 118–125. Feb.
[63] L.E. Jin, M. Wang, V.C. Galvin, T.C. Lightbourne, P.J. Conn, A.F.T. Arnsten, et al., Dendrimer-2PMPA selectively blocks upregulated microglial GCPII activity and improves cognition in a mouse model of multiple sclerosis, Nanoletters 6 (2) (2006) 126–132. Feb. 1.
[64] C.M. Pfeiffer, J.P. Hughes, D.A. Lacher, R.L. Bailey, R.J. Berry, M. Zhang, et al., A.A. Simen, K.A. Bordner, M.P. Martin, L.A. Moy, L.C. Barry, Cognitive carboxypeptidase inhibitor on superoxide dismutase transgenic mice after neonatal hypoxic-ischemic brain injury, Neurobiol. Dis. 148 (2021) 105201. Jan.
[65] K.J. Carpenter, S. Sen, E.A. Matthews, S.L. Flatters, K.M. Wozniak, B.S. Slusher, et al., Dual-target binding ligands with modulated pharmacokinetic properties in prostate adenocarcinoma: new strategy for treating age-related cognitive decline, Neuron 40 (4) (2004) 673–684. Nov 13.
[66] S. Ray Banerjee, M. Pullambhatla, C.A. Foss, A. Falk, Y. Byun, S. Nimmagadda, et al., Effect of chelators on the pharmacokinetics of (99 m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA), J. Med. Chem. 56 (15) (2013) 6108–6121. Aug. 8.
[67] J.K. Ransky, M.L. Beckelt, G.L. Wright, Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids, Int. J. Cancer 62 (5) (1995) 552–558. Sep. 4.
[68] S. Menezes, J. Schaefer, U. Bauder-Wüst, A. Afshar-Oromieh, W. Weichert, et al., Targeted alpha radiation therapy of metastatic castration-resistant prostate cancer: safety and efficacy, J. Nucl. Med. 58 (9) (2017) 1442–1449. Sep.
[69] W.P. Fendler, S. Reinhardt, H. Ilhan, A. Delker, G. Büchtler, C. Müller, Preclinical development of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endo/orthoradiotherapy of prostate cancer, J. Nucl. Med. 56 (6) (2015) 914–920. Jun.
[70] C.A. Unbricht, M. Bensowa, R. Schibli, C. Müller, Preclinical development of a novel PSMA targeting radioligand with improved pharmacokinetics and tissue distribution for improved prostate cancer therapy, Mol. Pharm. 15 (6) (2018) 2297–2306. Jun. 4.
[71] W. Weichert, U. Bauder-Wüst, A. Afshar-Oromieh, C. Kratochwil, W. Fendler, et al., Preliminary evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endo/orthoradiotherapy of prostate cancer, J. Nucl. Med. 56 (6) (2015) 1965–1977. May 20.
C. J. Choy, X. Ling, J. J. Geruntho, S. K. Beyer, J. D. Latoche, B. Langton-Webster, et al., 17Lu-labeled phosphonamide-based PSMA inhibitors: the effect of an albumin binder, Eur J Nucl Med Mol Imaging in prostate tumor-bearing mice, Theranostics 7 (2017) 1928–1939. Apr 27.

T. M. Jeitner et al. cancer, Mol. Imaging Biol. 18 (3) (2016) 402

M. Eder, M. Schafer, U. Bauer-Wu¨st, W. E. Hull, C. Wangler, W. Mier, et al., 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging, Bioconjug Chem. 23 (4) (2012) 688–697. Apr 18.

S. T. Tagawa, et al., Preclinical and radiopharmaceutical aspects of 68GaGa-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer, Pharmaceuticals 7 (7) (2014) 779–796. Basel Jun 30.

S. Cho, K.L. Gage, R.C. Mease, S. Senthamizhchelvan, D.P. Holt, A. Jeffrey, et al., Dual-time-point 64Cu-PSMA-617-PET/CT in patients suffering from prostate cancer, J. Label. Compd. Radiopharm. 62 (8) (2015) 523–532. Jun 30.

J. B. Nedorow, J. D. Kote, R. E. Day, J. Modi, T. Ganguly, D. Zeng, et al., Targeting PSMA with a Cu6-labeled phosphonate inhibitor for PET imaging of variant PSMA-expressing xenografts in mouse models of prostate cancer, Mol. Imaging Biol. 18 (3) (2016) 402–410. Jun 24.

S. B. Banerjee, M. Bollhardt, C.A. Umbricht, N. Gracheva, V.J. Tschan, G. Pellegrini, P. Bernhardt, et al., Solution thermodynamics and kinetics of metal complexation with a macrocyclic chelator for actinium-225 and 213Bi2+ with 18-membered macrocyclic ligands macrodip and Py-macrodip, Inorg. Chem. 61 (2) (2022) 801–806. Feb 14.

J. A. Hu, V. Brown, S.N. MacMillan, V. Radchenko, H. Yang, L. Wharton, et al., Chelating the alpha radionuclides 225Ac2+ and 213Bi2+ with 18-membered macrocyclic ligands macrodip and Py-macrodip, Inorg. Chem. 61 (2) (2022) 801–806. Feb 14.

B. Grubmüller, B. R. Kurland, C.M. Laymon, Y. Wu, et al., Preclinical dosimetry, imaging, and targeted radionuclide therapy studies of Labeled 17Lu-177Lu and 64Cu-68Ga-PSMA, J. Nucl. Med. Imaging 48 (8) (2021) 2642–2651. Jul 21.

T. M. Kalidindi, S.Y. Lee, K. Jou, G. Chakraborty, M. Saffidi, S.T. Tagawa, et al., A versatile strategy for selective salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals, Eur. J. Nucl. Med. Imaging 48 (8) (2021) 2642–2651. Jul 21.

B. A. Vaughn, A.J. Koller, Z. Chen, S.H. Ahn, C.S. Loveless, S.J. Cingoranelli, et al., A simple strategy to reduce the salivary gland and kidney uptake of PSMA-617 for PET imaging of metastasized castrate-resistant prostate cancer, J. Nucl. Med. 60 (6) (2019) 777–786. Jun 19.

R. Walczak, S. Krajewski, K. Szkliniarz, M. Sitarz, K. Abbas, J. Choi et al., K.A. Domnanich, C. Muller, M. Bene et al., Computer-assisted design of macrocyclic chelators for actinium-225 and 213Bi2+ as useful radiotherapeutics, Inorg. Chem. 60 (2) (2021) 623–632. Jan 18.

G. Paganelli, A. Sarreni, S. Severi, M. Santovinii, M.L. Belli, M. Monti, et al., Dosimetry and safety of 177Lu-PSMA-617 along with polyglutamate parotid gland protocol, Molecules 24 (3) (2019) 624. Feb 11.

M. Eder, O. Noels, M. Muller, U. Bauer-Wu¨st, Y. Remde, M. Schafer, et al., Preclinical and radiopharmaceutical aspects of 68GaGa-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer, Pharmaceuticals 7 (7) (2014) 779–796. Basel Jun 30.

S. Cho, K.L. Gage, R.C. Mease, S. Senthiamichelman, D.P. Holt, A. Jeffrey, et al., Biodistribution, tumor detection, and radiation dosimetry of 18F-DCEFB, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer, J. Nucl. Med. 53 (12) (2012) 1883–1891. Dec.

S. R. Banerjee, V. Kumar, A. Lisok, J. Chen, I. Mina, M. Brummett, et al., 17Lu-labeled low-molecular-weight agents for PSMA-targeted radionuclide therapy, Eur. J. Nucl. Med. Imaging 46 (12) (2019) 2545–2557. Nov.

B. Grumbüller, R.P. Baum, E. Capasso, A. Singh, Y. Ahmadi, B.A. Donzanti, et al., Synthesis and evaluation of a macrocyclic actinium-225 chelator, quality control and in vivo evaluation of 225Ac-crown-esh peptide, J. Nucl. Med. 50 (20) (2010) 2135–2141. Oct 7.

S. Hobernick, G. Wunderlich, E. Michler, T. Holscher, M. Walther, D. Seppelt, et al., Dual-time-point 64Cu-PSMA-617-PET/CT in patients suffering from prostate cancer, J. Label. Compd. Radiopharm. 62 (8) (2015) 523–532. Jun 30.

C. van der Polscher, et al., To reduce the salivary gland and kidney uptake of PSMA-617 for PET imaging of metastasized castrate-resistant prostate cancer, J. Nucl. Med. 60 (6) (2019) 777–786. Jun 19.

K. Szkliniarz, M. Sitarz, K. Abbas, J. Choi et al., K.A. Domnanich, C. Muller, M. Bene et al., Computer-assisted design of macrocyclic chelators for actinium-225 and 213Bi2+ as useful radiotherapeutics, Inorg. Chem. 60 (2) (2021) 623–632. Jan 18.

G. J.P. Deblonde, T. Lohrey, C.H. Booth, K.P. Carter, B.F. Parker, Å. Larsen, et al., Solution thermodynamics and kinetics of metal complexation with a hydroxypyridinone chelator designed for thorium-227 targeted alpha therapy, Inorg. Chem. 57 (22) (2018) 14327–14346. Nov 19.

G.J.P. Deblonde, T. Lohrey, C.H. Booth, K.P. Carter, B.F. Parker, Å. Larsen, et al., Solution thermodynamics and kinetics of metal complexation with a hydroxypyridinone chelator designed for thorium-227 targeted alpha therapy, Inorg. Chem. 57 (22) (2018) 14327–14346. Nov 19.
Dietary nitrate supplementation prevents radiotherapy-induced xerostomia, Elife 10 (2021). Sep 28.

[258] L. Li, H. Wang, L. Hu, X. Wu, B. Zhao, Z. Fan, et al., Age associated decrease of sialin in salivary glands, Biotech. Histochem. 93 (7) (2018) 565–511. May 23.

[259] L. Dubeix, N. Pietrancosta, A. Cabaye, I. Fanget, C. Debaker, P.-A. Giroimini, et al., Amino acids bearing aromatic or heteroaromatic substituents as a new class of ligands for the lysosomal sialic acid transporter sialin, J. Med. Chem. 63 (15) (2020) 8231–8249. Aug 13.

[260] J. Loderer-Gadaczek, V. Gieselmann, M. Eckhardt, Vesicular uptake of N-acetylaspartylglutamate is catalysed by sialin (SLC17A5), Biochem. J. 454 (1) (2013) 31–38. Aug 15.

[261] L. Qin, X. Liu, Q. Sun, Z. Fan, D. Xia, G. Ding, et al., Sialin (SLC17A5) functions as a nitrate transporter in the plasma membrane, Proc. Natl. Acad. Sci. USA 109 (23) (2012) 13434–13439. Aug 14.

[262] S.S. Chang, V.E. Reuter, W.D. Heston, N.H. Bander, L.S. Grauer, P.B. Gaudin, Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovascularisation, Cancer Res. 59 (13) (1999) 3192–3198. Jul 1.

[263] M.R. Naunheim, H.W. Lin, W.C. Faquin, D.T. Lin, Intercalated duct lesion of the parotid, Head Neck Pathol. 6 (3) (2012) 373–376. Sep.

[264] Y. Mok, Y.H. Pang, M. Teh, F. Petersson, Hybrid intercalated duct lesion of the parotid: diagnostic challenges of a recently described entity with fine needle aspiration findings, Head Neck Pathol. 10 (2) (2016) 269–274. Jun.

[265] N. Pietrancosta, C. Anne, H. Prescher, R. Ruizo, C. Saget, C. Debacker, et al., Successful prediction of substrate-binding pocket in SLC17 transporter sialin, J. Biol. Chem. 287 (14) (2012) 13813–13817. Mar 30.

[266] Y. Xia, S. Szep, Z. Lu, The antioxidant role of sialic acid in the pathogenesis of cystic fibrosis and other inflammation-related diseases, Proc. Natl. Acad. Sci. USA 106 (48) (2009) 20515–20519. Dec 1.

[267] J.D. Chandler, B.J. Day, Thioctanate: a potentially useful therapeutic agent with host defense and antioxidant properties, Biochem. Pharmacol. 84 (11) (2012) 1381–1387. Dec 1.

[268] C. Guo, M.J. Davies, C.L. Hawkins, Role of thioctanate in the modulation of myeloperoxidase-derived oxidant induced damage to macrophages, Redox. Biol. 36 (2020), 101666. Sep.

[269] P. Aggarwal, K.A. Hutcherson, R. Yu, W. Wang, C.D. Fuller, A.S. Garden, et al., Genetic susceptibility to patient-reported xerostomia among long-term oropharyngeal cancer survivors, Sci. Rep. 12 (1) (2022) 6662. Apr 22.

[270] E.H.N. Fow, Z. Chen, D.L.W. Kwong, O.L.T. Lam, Salivary anionic changes after radiotherapy for nasopharyngeal carcinoma: a 1-year prospective study, PloS One 11 (3) (2016) e0152817. Mar 31.

[271] J. Li, Z. Shan, G. Ou, X. Liu, C. Zhang, B.J. Baum, et al., Structural and functional characteristics of irradiation damage to parotid glands in the miniature pig, Int. J. Radiat. Oncol. Biol. Phys. 62 (5) (2005) 1510–1516. Aug 1.

[272] S.L. Wang, J. Li, X.Z. Zhu, K. Sun, X.Y. Liu, Y.G. Zhang, Dialographic characterization of the normal parotid gland of the miniature pig, Dentomaxillofac. Radiol. 27 (3) (1998) 178–181. May.

[273] P. Backhaus, B. Noto, N. Avramovic, L.S. Grubert, S. Huss, M. Bogemann, et al., Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives, Eur. J. Nucl. Med. Mol. Imaging 45 (5) (2018) 860–877. May.